Trial Profile
An investigator-initiated phase I/IIa trial of subretinal injection of DVC1-0401 as neuroprotective gene therapy for retinitis pigmentosa
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2022
Price :
$35
*
At a glance
- Drugs DVC1 0401 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- 06 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2019 Status changed from not yet recruiting to recruiting.
- 05 Nov 2018 New trial record